宏川智慧(002930.SZ):常州華潤56.91%股權及常熟華潤100%股權已過户至公司名下
格隆匯6月1日丨宏川智慧(002930.SZ)公佈,2020年5月6日,公司召開2020年第三次臨時股東大會,審議通過了《關於公司重大資產購買方案的議案》、《關於公司符合重大資產購買條件的議案》等與本次重大資產重組相關的議案,同意公司以現金方式受讓華潤化學材料有限公司(“華潤化學”)持有的常州華潤化工倉儲有限公司(“常州華潤”)56.91%股權及至溢投資有限公司(“至溢投資”)持有的常熟華潤化工有限公司(“常熟華潤”)100%股權。
截至公告披露之日,上述股權已過户至宏川智慧名下。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.